Replies to post #111436 on Biotech Values

[DewDiligence]

What about going forward? Do you think the results of the FDA-required trial will be in TEVA's favor, and how long would you expect such a trial to take?

I expect that Teva’s program for low-volume Copaxone will now be supplanted by the program for thrice-weekly Copaxone (#msg-58091689).